Black Hawk Acquisition (BKHA) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TScan Therapeutics is the larger company by market cap ($9.9 million vs $7.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | TCRX |
|---|---|---|
| Share price | $1.85 | $0.1459 |
| Market cap | $7.68M | $9.89M |
| 1-day change | -71.45% | +2.24% |
| YTD return | — | -85.41% |
| 1-year return | — | -84.85% |
| 5-year return | — | -98.33% |
| P/E ratio (TTM) | 5.61 | — |
| EPS (TTM) | $0.33 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.32M |
| Revenue growth (YoY) | — | +266.65% |
| Net income (latest FY) | $1.33M | $-129.77M |
| Operating margin | — | -1315.38% |
| Net margin | — | -1256.81% |
| 52-week high | $23.00 | $1.47 |
| 52-week low | $1.75 | $0.14 |
| Distance from 52-week high | -91.96% | -90.07% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +585.40% |
| Average volume | 101.40K | 766.11K |
| Shares outstanding | 4.15M | 63.50M |
| Employees | — | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
BKHA vs TCRX FAQ
Which is bigger, Black Hawk Acquisition or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $9.89M compared with $7.68M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.